| Biomarker ID | 935 |
| PMID | 22640805 |
| Year | 2012 |
| Biomarker | GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (CCNB1): T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway |
| Experiment | BPC (benign prostates containing PCa) VS BP |
| Type of Biomarker | Diagnostic |
| Cohort | Confirmation Set: 37 PCas and 36 unmatched benign prostates containing PCa (BPCs) and were contrasted with 28 benign prostates (BPs) from patients free of PCa. Validation Set: independent set of 51 BPCs and BPs (GSE17951) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001) |
| Method Used | quantitative real time polymerase chain reactions (qRT-PCR) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | GPR37, SOX4, CCNB1, TOP2A, DLG5, NACA, NR2C2, PDCD5, IDSP1 |